Common Cold
The common cold is a mild viral infectious disease of the upper respiratory tract that affects the nose, throat, sinuses, and larynx, characterized by symptoms like coughing, sore throat, runny nose, sneezing, headache, and fever. While there is no cure and treatments focus on symptom relief, the condition typically resolves on its own within 2–14 days, though some symptoms may last up to three weeks.
Health Outcomes
- Absence of Serious Adverse Events
- Absence of Serious Side Effects
- Absence of Serious Symptoms such as Septic Shock
- Accelerated Recovery of B Cell-Mediated Respiratory Immunity
- Accelerated Recovery within 3 Days
- Achieved Complete Symptom Cessation
- Asymptomatic or Mild Symptoms
- Enhanced Antibody Secretion
- Enhanced Early Immune Response
- Enhanced Immune Capacity
- Enhanced Immune System
- Enhanced Immunological Defense Against Respiratory Viral Infections
- Enhanced Innate Antiviral Immune Response
- Enhanced Interferon Production
- Enhanced Non-specific Immune Defense
- Enhanced Protection Against Infection
- Enhanced Resistance to Infections
- Enhanced Resistance to Respiratory Infections
- Improved Clinical Protection Against Viral Challenge
- Improved Cure Rate
- Improved Disease Resolution
- Improved Humoral Immune Response
- Improved Immune Response to Adenovirus
- Improved Immune System Activity
- Improved Immunity Biomarkers
- Improved Infection Protection
- Improved Mucosal Immunity
- Improved Recovery Rate
- Improved Resistance against Infections
- Improved Resistance to Common Cold
- Improved Resistance to Viral Infections
- Improved Respiratory Infection Resistance
- Improved Response
- Improved Serum Immunity
- Improved Symptom Resolution
- Improved Symptom Resolution Rate
- Improved Vaccine-Specific Secretory IgA Levels in Saliva
- Increased Days Without Illness
- Increased Fever-Free Days
- Increased Incidence of Upper Respiratory Symptoms
- Increased Incidence of Upper Respiratory Tract Infections
- Increased Interferon Production
- Increased Mucosal B-Cell Responses
- Increased Salivary Immunoglobulin A Secretion
- Increased Secretory IgA Production
- Increased URTI-Free Rate
- Induced Antigen-Specific Protective Mucosal Immune Response
- Inhibition of RSV Replication
- Modulated Upper Airway Immune Response
- Nasopharyngeal Colonization
- No Reduction in Antibiotic Use
- No Significant Reduction in URTI Incidence
- Prevented Upper Respiratory Tract Infection
- Recovered Without Further Complications
- Reduced Acute Otitis Media
- Reduced Acute Respiratory Tract Infection Incidence
- Reduced Antibiotic Duration
- Reduced Antibiotic Usage
- Reduced Antibiotic and Antiviral Use
- Reduced Antimicrobial Use
- Reduced Bloody Nasal Mucus
- Reduced Cervical Lymphadenopathy Frequency
- Reduced Cold Incidence
- Reduced Cold Recurrence
- Reduced Cold Symptoms
- Reduced Cold and Flu Incidence
- Reduced Cold/Flu Medication Use
- Reduced Cold/Flu Severity
- Reduced Community-Acquired Infection
- Reduced Cough Duration
- Reduced Day Care Absence
- Reduced Day Care Absenteeism Due to Infections
- Reduced Days with Runny Nose Symptoms
- Reduced Duration of Acute Respiratory Infection
- Reduced Duration of Antipyretic Therapy
- Reduced Duration of Common Cold
- Reduced Duration of Common Cold Episodes
- Reduced Duration of Common Cold Symptoms
- Reduced Duration of Nasal Symptoms
- Reduced Duration of Respiratory Infection
- Reduced Duration of Respiratory Tract Infection Episode
- Reduced Duration of Respiratory Tract Infections
- Reduced Duration of URTI-Associated Symptoms
- Reduced Duration of Upper Respiratory Symptoms
- Reduced Duration of Upper Respiratory Tract Illness
- Reduced Duration of Upper Respiratory Tract Infection
- Reduced Enterovirus Replication
- Reduced Episode Duration
- Reduced Fever
- Reduced Fever Duration During CID
- Reduced Fever Duration During Common Cold
- Reduced Frequency of Pharyngitis
- Reduced Frequency of Recurring Colds
- Reduced Hoarseness
- Reduced Hoarseness Duration
- Reduced Impact of Rhinovirus Infection
- Reduced Incidence Rate of URTIs
- Reduced Incidence of Cold/Flu Days
- Reduced Incidence of Colds
- Reduced Incidence of Common Infections
- Reduced Incidence of Community-Acquired Colds
- Reduced Incidence of Influenza-like Illness
- Reduced Incidence of Recurring Colds
- Reduced Incidence of Respiratory Illness
- Reduced Incidence of Upper Respiratory Tract Infections
- Reduced Infection Incidence
- Reduced Infection Rate
- Reduced Infectious RV Titer
- Reduced Influenza Symptoms
- Reduced Laryngitis
- Reduced Local Immunoglobulin Production
- Reduced Mean Number of Infections per Child
- Reduced Nasal Colonization
- Reduced Nasal Congestion
- Reduced Nasal Stuffiness
- Reduced Nasal Symptom Score
- Reduced Nasal Symptoms
- Reduced Otitis Media Episode Incidence
- Reduced Parental Absenteeism from Work
- Reduced Pathogen Attachment
- Reduced Pathogen Growth
- Reduced Pharyngitis/Tonsillitis Incidence
- Reduced Postinfective Symptoms
- Reduced Recovery Time
- Reduced Respiratory Infections in Infants
- Reduced Respiratory Pathogen Load
- Reduced Respiratory Tract Infection Episode
- Reduced Rhinovirus Nasal Lavage Titer
- Reduced Runny Nose Duration
- Reduced School Absence Days
- Reduced School Absenteeism Due to Infectious Diseases
- Reduced Secretion Consistency
- Reduced Severity of Common Cold Symptoms
- Reduced Severity of Nasal Congestion and Runny Nose
- Reduced Severity of URTIs
- Reduced Sick Leave Days
- Reduced Sneezing Symptoms
- Reduced Sore Throat Duration
- Reduced Sore Throat Severity
- Reduced Symptom Duration
- Reduced Time to Symptom Resolution
- Reduced Total Nasal Symptom Score
- Reduced URTI Duration
- Reduced URTI Symptoms
- Reduced Upper Respiratory Infection
- Reduced Upper Respiratory Symptoms
- Reduced Upper Respiratory Tract Infection
- Reduced Upper Respiratory Tract Infection Days
- Reduced Upper Respiratory Tract Infection Duration
- Reduced Upper Respiratory Tract Infection Severity
- Reduced Upper Respiratory Tract Infection Symptom Severity
- Reduced Upper Respiratory Tract Infection Symptoms
- Reduced Upper Respiratory Tract Infection Treatment Duration
- Reduced Use of URTI-Associated Medication
- Reduced Viral Activity
- Reduced Viral Respiratory Infection
- Reduced Virus Titers in Bronchoalveolar Lavage Fluid
- Restored Microbial Community Structure in Upper Respiratory Tract
- Shortened Treatment Course
- Unchanged Severity of URTI
- Upper Respiratory Tract Colonization